Rong Liu

US Patent:

7129055, Oct 31, 2006

Filed:

Dec 11, 2000

Appl. No.:

09/734221

Inventors:

Dan R. Littman - New York NY, US
Hongkui Deng - Worcester MA, US
Wilfried Ellmeier - New York NY, US
Nathaniel R. Landau - New York NY, US
Rong Liu - New York NY, US

Assignee:

New York University - New York NY

International Classification:

C01N 33/53
C01N 33/533
C12N 15/00
C12N 15/48
C12N 15/07
C12N 15/09
C12N 5/28
C07K 16/28

US Classification:

435 72, 435 721, 435 724, 435 78, 435 793, 435325, 435 691, 435440, 53038822

Abstract:

Entry of HIV-1 into target cells requires cell surface CD4 as well as additional host cell cofactors. A cofactor required for infection with virus adapted for growth in transformed T cell lines was recently identified and named fusin. Fusin, however, does not promote entry of macrophage-tropic viruses that are believed to be the key pathogenic strains in vivo. It has now been determined that the principal cofactor for entry mediated by the envelope glycoproteins of primary macrophage-tropic strains of HIV-1 is CC-CKR5, a receptor for the β-chemokines RANTES, MIP-1α, and MIP-1β.

US Patent:

7592315, Sep 22, 2009

Filed:

Nov 1, 2005

Appl. No.:

11/264509

Inventors:

Rong Liu - Scotch Plains NJ, US
Rumin Zhang - Edison NJ, US
Rong Kong - Scotch Plains NJ, US

Assignee:

Schering Corporation - Kenilworth NJ

International Classification:

A01N 37/18
A61K 38/16
A61K 38/21
A61K 39/42
G01N 33/00

US Classification:

514 13, 514 8, 514 11, 514 5, 514 6, 514 9, 514 7, 436 87, 530317, 530326, 435 691

Abstract:

The present invention provides, inter alia, peptide compositions and methods for treating and preventing Flaviviridae virus (e. g. , hepatitis C virus) infections.

US Patent:

20070298096, Dec 27, 2007

Filed:

Oct 26, 2005

Appl. No.:

11/666528

Inventors:

Rong Liu - Warren NJ, US
Michael Corbo - Flemington NJ, US
Jatin Desai - Plainsboro NJ, US
Gerard Frunzi - Douglaston NY, US
Xiaohong Qi - Irvington NJ, US
Candice Choi - Palisades Park NJ, US
Rahul Gandhi - Plainsboro NJ, US
Atef Boulos - Rockaway NJ, US

International Classification:

A61K 9/48
A61K 31/52
A61P 25/04

US Classification:

424451000, 514263100

Abstract:

The onset of activity of a first analgesic/antipyretic composition containing an analgesic/antipyretic effective amount of acetaminophen, caffeine and, optionally, aspirin is shortened by incorporating in the first composition an onset of analgesic/antipyretic activity shortening amount of at least one alkaline agent whereby a second composition is produced. The second composition being bioequivalent to the first composition but having a shorter onset of analgesic/antipyretic activity than the first composition.

US Patent:

20100119483, May 13, 2010

Filed:

Jul 23, 2009

Appl. No.:

12/508095

Inventors:

Rong Liu - Scotch Plains NJ, US
Rumin Zhang - Edison NJ, US
Rong Kong - Scotch Plains NJ, US

International Classification:

A61K 38/21
C07K 2/00
A61K 38/02
A61K 39/395
C07H 21/00
C12N 15/74
C12N 5/071
C12P 21/02
A61P 31/12
A61P 31/14
A61P 31/18
A61P 37/04

US Classification:

424 857, 530300, 514 2, 4241301, 424 854, 536 231, 4353201, 435325, 435 691

Abstract:

The present invention provides, inter alia, peptide compositions and methods for treating and preventing Flaviviridae virus (e.g., HCV) infections.

US Patent:

20120297390, Nov 22, 2012

Filed:

May 17, 2011

Appl. No.:

13/109560

Inventors:

Richard B. Hull - Chatham NJ, US
Rong Liu - Sterling VA, US
Anil Nigam - Stamford CT, US
Florian Pinel - New York NY, US
Frederick Y. Wu - Greenwich CT, US

Assignee:

INTERNATIONAL BUSINESS MACHINES CORPORATION - Armonk NY

International Classification:

G06F 9/46

US Classification:

718102

Abstract:

Execution of flexible workflows using artifacts is described. A workflow execution engine is configured to instantiate a process execution (PE) artifact. The PE artifact includes one or more transitions. The workflow execution engine is further configured to execute the one or more transitions and determine if any of the one or more transitions are new or modified. The workflow execution engine is additionally configured to load and execute new or modified transitions, without reinstantiating the PE artifact, responsive to determining that at least one new or modified transitions exist.

US Patent:

62585274, Jul 10, 2001

Filed:

May 21, 1997

Appl. No.:

8/861105

Inventors:

Dan R. Littman - New York NY
Hongkui Deng - Worcester MA
Wilfried Ellmeier - New York NY
Nathaniel R. Landau - New York NY
Rong Liu - New York NY

Assignee:

The Aaron Diamond Aids Research Center - New York NY
New York University - New York NY

International Classification:

C12Q 170
G01N 33567
C12N 510

US Classification:

435 5

Abstract:

Entry of HIV-1 into target cells requires cell surface CD4 as well as additional host cell cofactors. A cofactor required for infection with virus adapted for growth in transformed T cell lines was recently identified and named fusin. Fusin, however, does not promote entry of macrophage-tropic viruses that are believed to be the key pathogenic strains in vivo. It has now been determined that the principal cofactor for entry mediated by the envelope glycoproteins of primary macrophage-tropic strains of HIV-1 is CC-CKR5, a receptor for the. beta. -chemokines RANTES, MIP-1. alpha. , and MIP-1. beta.

US Patent:

60571020, May 2, 2000

Filed:

Aug 8, 1997

Appl. No.:

8/907468

Inventors:

Nathaniel R. Landau - New York NY
Richard A. Koup - Southlake TX
Rong Liu - New York NY
William Paxton - Amsterdam, NL

Assignee:

The Aaron Diamond Aids Research Center - New York NY

International Classification:

C12Q 168
C12Q 170

US Classification:

435 6

Abstract:

Entry of HIV-1 into target cells requires cell surface CD4 as well as additional host cell cofactors. A cofactor required for infection with virus adapted for growth in transformed T cell lines was recently identified and named fusin. Fusin, however, does not promote entry of macrophage-tropic viruses that are believed to be the key pathogenic strains in vivo. It has now been determined that the principal cofactor for entry mediated by the envelope glycoproteins of primary macrophage-tropic strains of HIV-1 is CC-CKR5, a receptor for the. beta. -chemokines RANTES, MIP-1. alpha. , and MIP-1. beta. It has also been found that individuals who are homozygous for a mutation of the CKR-5 receptor are resistent to HIV infection; in vitro infection requires a 1000-fold higher dose of HIV than normal cells. The mutation results in complete suppression of CKR-5 expression.

US Patent:

59393203, Aug 17, 1999

Filed:

Jun 19, 1996

Appl. No.:

8/666020

Inventors:

Dan R. Littman - New York NY
Hongkui Deng - New York NY
Wilfried Ellmeier - New York NY
Nathaniel R. Landau - New York NY
Rong Liu - New York NY

Assignee:

New York University - New York NY
The Aaron Diamond Aids Research Center - New York NY

International Classification:

C12N 506
C12N 510
C12N 508

US Classification:

435325

Abstract:

Entry of HIV-1 into target cells requires cell surface CD4 as well as additional host cell cofactors. A cofactor required for infection with virus adapted for growth in transformed T cell lines was recently identified and named fusin. Fusin, however, does not promote entry of macrophage-tropic viruses that are believed to be the key pathogenic strains in vivo. It has now been determined that the principal cofactor for entry mediated by the envelope glycoproteins of primary macrophage-tropic strains of HIV-1 is CC-CKR5, a receptor for the. beta. -chemokines RANTES, MIP-1. alpha. , and MIP-1. beta.